Skip to main content
OpenTrials
Completed

NCT Number: NCT06167954

Safety and Usability of a Robotic Gait Device for Children and Adolescents With Neurological or Neuromuscular Disease in Their Natural Environment

The goal of this clinical trial is to analyze the usability and safety of the robotic gait device EXPLORER in children with cerebral palsy, acquired brain injury and spinal muscular atrophy.

Participants will use the exoskeletons in their home and the community and variables regarding safety and usability will be measured and recorded.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Infantil Universitario Niño Jesús-Servicio de Rehabilitación, Madrid, Spain

Loading trial locations.

About this study

Neurological and neuromuscular diseases are the main cause of motor disability in children, leading to the inability to stand and walk in many cases. Robotic devices are a useful tool in the rehabilitation of these children, but most of them are designed to be used in the clinical setting. EXPLORER is a robotic device designed to assist gait in children with motor disability in their homes and the community. The aim of this study is to analyze the safety and usability of the EXPLORER in children with cerebral palsy, acquired brain injury and spinal muscular atrophy.

A test phase will be conducted in order to make some final modifications and improve the device. Some participants of the sample will use the device in 1-3 occasions in a controlled environment.

After these modifications, participants will use the final version of the device in 8 different occasions in their homes and the community in order to prove its safety and usability.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of cerebral palsy, acquired brain injury or spinal muscular atrophy
  • Medical authorization for standing, gait training and weight bearing.
  • Informed consent signed by legal guardians.
  • Maximum user weight of 60 kg.
  • Hip width (between greater trochanters) ≤40 cm.
  • Length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 21cm to 36cm.
  • Tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 20cm to 35cm.
  • Shoe size ≤40 (EU)

Exclusion criteria

  • Medical contraindications for standing or walking.
  • Non-reducible contractures or heterotropic ossifications above the degrees allowed by the device or out of the trajectory imposed by the device
  • Spasticity equal to 4 on the Modified Ashworth Scale at the time of use of the device.
  • More than 20º of hip and/or knee non-reducible contractures at the time of using the exoskeleton.
  • Necessity to walk with more than 5º of hip abduction.
  • Impossibility to reach 5º of ankle dorsiflexion with ir without orthoses.
  • Lower length dysmetria that cannot be mitigated with a wedge under the foot.
  • Skin lesion on parts of the lower extremities that are in contact with the device.
  • History of fracture without trauma.
  • Presence of other conditions causing exercise intolerance (such as uncontrolled hypertension, coronary artery disease, arrhythmia, congestive heart failure, severe pulmonary disease).
  • Conductual disorders that may interfere with the use of the device or their participation in the study, like impulsiveness.
  • Allergy to any of the EXPLORER materials: cotton, nylon, polyester, PPS, PEEK or ABS.

Treatment and study plan

EXPLORER

Device

8 sessions of use of the device in the home and the community of the participants

Primary outcomes

  1. Serious Adverse Events

    Time frame: through study completion, along 8 weeks

    occurrence of any serious adverse event to the participant or the caregiver

  2. Falls prevalence

    Time frame: through study completion, along 8 weeks

    Number of falling events occurred from the participant or caregiver

  3. Skin integrity

    Time frame: through study completion, along 8 weeks

    Occurrence of any injury of the skin in the areas of contact and produced by the use of the device

  4. Pain (Visual Analogic Scale)

    Time frame: through study completion, along 8 weeks

    pain measured by the Visual Analogic Scale (VAS) by the participant and the caregiver, scored from 0 to 10, being 0 "no pain" and 10 "unbearable pain"

  5. Spasticity

    Time frame: through study completion, along 8 weeks

    spasticity measured by the Modified Ashworth Scale (MAS), scored from 0 (no spasticity) to 4 (affected part in rigid flexion or extension)

  6. Heart rate

    Time frame: through study completion, along 8 weeks

    measurement of heart rate

  7. Oxygen saturation

    Time frame: through study completion, along 8 weeks

    measurement of Oxygen saturation when medical prescription

  8. Donning and doffing time

    Time frame: through study completion, along 8 weeks

    Time to don and doff the device to each participant

  9. Number of steps

    Time frame: through study completion, along 8 weeks

    Number of steps taken provided by the device

  10. Walking time

    Time frame: through study completion, along 8 weeks

    Walking time provided by the device

  11. Interventions of the investigators

    Time frame: through study completion, along 8 weeks

    The number of times that the investigators have to intervene in the session in order to avoid damage when the device is being used by the caregiver

  12. Participant satisfaction

    Time frame: at the end of the intervention, 8th week

    Satisfaction of the participant (caregiver) with the device measured by the Quebec User Evaluation of Satisfaction with Assistive Technology 2.0. (QUEST 2.0), scored with a Likert type scale from 0 to 5, being 0 the lowest satisfaction and 5 the highest possible satisfaction with the device

  13. Blood pressure

    Time frame: through study completion, along 8 weeks

    measurement of blood pressure

Secondary outcomes

  1. Acceptability

    Time frame: at the end of the intervention, 8th week

    Analysis of the drop-out rate during the study period

  2. Accessibility of the participant

    Time frame: through study completion, along 8 weeks

    Rate of the participants suitable to use the device

  3. Accessibility of the house

    Time frame: through study completion, along 8 weeks

    Rate of the houses suitable to use the device

  4. Accessibility of the exterior spaces

    Time frame: through study completion, along 8 weeks

    Rate of the exterior spaces that are suitable to use the device

Sponsors and collaborators

Lead sponsor

MarsiBionics

Industry

Collaborators

  • Hospital General Universitario Gregorio Marañon
  • Hospital Infantil Universitario Niño Jesús, Madrid, Spain
  • Hospital Universitario 12 de Octubre
  • Hospital Universitario La Paz

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 13, 2023
Registry last updated
Sep 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.